BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Antaimmu BioMed Co., Ltd.

 

Company Info

Name /Antaimmu BioMed Co., Ltd.

Address /Rm. C4, 3F., No. 1, Lixing 1st Rd., East Dist., Hsinchu City, Taiwan (R.O.C.)

Website /https://antaimmu.com/

Presenter

Name /San-Tai Shen

Title /Chairman & CEO

Email /santai.shen@antaimmu.com

Telephone /(Work) +886-3-5797779

Fax /+886-3-5797776

Mobile /

Company Type

Biotechnology,Diagnostics

About the Company

AnTaimmu BioMed (ATBM) is a new drug discovery company focusing on developing novel therapeutic antibodies and protein drugs. Based on our bioinformatic and protein science technologies, we have constructed human synthetic antibody libraries, naive antibody libraries, and antibody libraries from immunized animals for screening specific monoclonal antibodies of cancer target molecules. We value humanity and are committed to improving human health. Since the outbreak of COVID-19, we are also dedicated to the development of SARS CoV-2 neutralizing antibodies as therapeutic drugs. ATBM partners with PBF and Eirgenix and launched Vstrip COVID-19 antigen rapid test in the middle of 2020.

Brief Description of main products or services

ATBM® has constructed antibody libraries and protein libraries with high complexity, and set up a highly efficient platform for protein/antibody production and antibody screening. We focus on developing Neobody™, a new generation multivalent antibody, which enhances the capability of our immune system to detect and destroy tumor cells and avoids attacks on normal cells.

Cancer Drugs:

Our primary goal is to develop novel immunotherapy antibody drugs for cancer with enhanced efficiency and fewer side effects. As a biologics drug development company, we will develop our drug until an early phase of clinical trial, and then cooperate with an international pharmaceutical company to complete development of the clinical drug.

COVID-19 Therapeutic Drugs:

We are also dedicated to developing SARS CoV-2 neutralizing antibodies and have screened several candidates with high affinity and neutralization ability. We are constructing the candidates into the form of Neobody™, which is designed to bind to multiple different epitopes on SARS CoV-2 spike protein, preventing virus escape mutation.

Antibody Services:

In addition to our proprietary drug development, we also provide antibody and protein services, including gene cloning form hybridoma, antibody humanization, monoclonal antibody production, customized monoclonal antibodies, and antibody affinity maturation for academic institutions and pharmaceutical companies.

Contact Person

Name /Hannah Chang

Email /hannah.chang@antaimmu.com

Phone /+886-3-5797779 #122